NVCT - Nuvectis Pharma, Inc.
IEX Last Trade
5.34
0.150 2.809%
Share volume: 551
Last Updated: Fri 27 Dec 2024 08:15:07 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$5.19
0.15
2.89%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
9.61%
1 Month
-4.92%
3 Months
-18.77%
6 Months
-19.94%
1 Year
-40.17%
2 Year
-31.45%
Key data
Stock price
$5.34
DAY RANGE
$4.97 - $5.35
52 WEEK RANGE
$4.70 - $12.10
52 WEEK CHANGE
-$39.81
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Ronald E. Bentsur
Region: US
Website: nuvectis.com
Employees: 8
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: nuvectis.com
Employees: 8
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Nuvectis Pharma focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Recent news